The first clinical procedure has taken place on a patient using radioactive holmium-166 microspheres that were activated at the BR2 research reactor in Mol, Belgium, Quirem Medical said.
We use cookies for analytics and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site. To find out more, including how to change your settings, see our Cookie Policy
By David Dalton
16 June 2021